Mutational analysis in podocin-associated hereditary nephrotic syndrome in Polish patients : founder effect in the Kashubian population by Lipska, Beata S. et al.
HUMAN GENETICS • ORIGINAL PAPER
Mutational analysis in podocin-associated hereditary
nephrotic syndrome in Polish patients: founder effect
in the Kashubian population
Beata S. Lipska & Irena Balasz-Chmielewska & Lucyna Morzuch & Kacper Wasielewski &
Dominika Vetter & Halina Borzecka & Dorota Drozdz & Agnieszka Firszt-Adamczyk &
Ewa Gacka & Tomasz Jarmolinski & Joanna Ksiazek & Elzbieta Kuzma-Mroczkowska &
Mieczyslaw Litwin & Anna Medynska & Magdalena Silska & Maria Szczepanska &
Marcin Tkaczyk & Anna Wasilewska & Franz Schaefer & Aleksandra Zurowska &
Janusz Limon
Received: 7 March 2013 /Revised: 22 March 2013 /Accepted: 27 March 2013 /Published online: 5 May 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Hereditary nephrotic syndrome is caused by mu-
tations in a number of different genes, the most common
being NPHS2. The aim of the study was to identify the
spectrum of NPHS2 mutations in Polish patients with the
disease. A total of 141 children with steroid-resistant
nephrotic syndrome (SRNS) were enrolled in the study.
Mutational analysis included the entire coding sequence
and intron boundaries of the NPHS2 gene. Restriction frag-
ment length polymorphism (RFLP) and TaqMan genotyping
assay were applied to detect selected NPHS2 sequence
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variants in 575 population-matched controls. Twenty patients
(14 %) had homozygous or compound heterozygous
NPHS2 mutations, the most frequent being c.1032delT
found in 11 children and p.R138Q found in four
patients. Carriers of the c.1032delT allele were exclu-
sively found in the Pomeranian (Kashubian) region,
suggesting a founder effect origin. The 14 % NPHS2
gene mutation detection rate is similar to that observed
in other populations. The heterogeneity of mutations
detected in the studied group confirms the requirement
of genetic testing the entire NPHS2 coding sequence in
Polish patients, with the exception of Kashubs, who
should be initially screened for the c.1032delT deletion.
Keywords NPHS2 . Steroid-resistant nephrotic syndrome .
Founder effect . Kashubian population
Introduction
Steroid-resistant nephrotic syndrome (SRNS) occurs at an
estimated incidence of 1 per 200,000 children. Genetic causes
can be identified in nearly 50 % of affected children with this
highly heterogeneous disorder (Löwik et al. 2009; Benoit et
al. 2010). Genetic forms of SRNS do not respond to intensi-
fied immunosuppressive treatment and progress inevitably to
end-stage kidney disease, but, on the other hand, have mini-
mal risk of post-transplant recurrence. Hence, genetic testing
is of eminent clinical relevance in this complex group of
patients (Jungraithmayr et al. 2011; Santín et al. 2011a).
In hereditary SRNS, abnormalities in podocyte-specific
genes cause structural defects of the glomerular filtration
barrier (Hinkes et al. 2007; Löwik et al. 2009). Defective
genes involve the structure and function of the slit dia-
phragm (e.g. NPHS1, NPHS2), the actin cytoskeleton (e.g.
ACTN4, INF2) or podocyte differentiation (WT1) (Löwik et
al. 2009; Benoit et al. 2010; Santín et al. 2011a).
NPHS2 encodes podocin, a membrane protein that links
the slit diaphragm protein nephrin to the cytoskeleton.
NPHS2 mutations constitute the most common genetic
cause of SRNS (Hinkes et al. 2007; Santín et al. 2011b;
Lipska et al. 2013). The NPHS2 gene is located on chromo-
some 1p25-31 and consists of eight exons. To date, approx-
imately 120 different point mutations localised along the
entire coding sequence of the gene have been reported.
The aim of the study was to determine the prevalence and
spectrum of NPHS2 gene mutations in a nation-wide cohort
of Polish children with SRNS and to compare the spectrum
of mutations with those described in other European
populations.
Materials and methods
Mutational screening
A total of 141 patients with a clinical diagnosis of SRNS
from 13 Polish paediatric nephrology centres were enrolled
in the study. Detailed analysis of the clinical parameters of
the studied group is out of the scope of the current report
and will be the subject of a separate study.
DNAwas extracted from blood samples using the standard
phenol–chloroform procedure. The complete coding sequence
of the NPHS2 gene, including splice junctions, was subject to
direct bi-directional sequencing (Applied Biosystems). All nov-
el variants were verified in the dbSNP, the 1000 Genomes
catalogue and the NHLBI Exome Sequencing Project. The
trans-character of the compound heterozygous cases was con-
firmed by testing parents. To assess the effect of the detected
novel sequence variants on the structure and function of the
protein, a number of bioinformatics tools were used, including
the UCSC Genome Bioinformatics and UniProtKB web re-
sources, alongwith the PolyPhen-2 and SIFTonline algorithms.
The Human Splicing Finder and ESEfinder web interfaces were
used to evaluate the potential effect on the splicing process.
Population genotyping
Dried blood specimens from 575 consecutively screened
neonates representative for the Kashubian districts of North
Poland were used as a population-matched control group.
DNA was extracted from 1–3-mm2 pieces of dried blood
specimens that were incubated in 50 μl of TE buffer at
95 °C for 1 h; after incubation, samples were centrifuged
at room temperature at 1,400×g for 10 min to eliminate
physical contamination. The supernatant was used as the
DNA template. The NPHS2 p.R229Q genotype was deter-
mined by restriction fragment length polymorphism (RFLP)
using Bsu15I (ClaI) enzyme (Thermo Scientific), while the
c.1032delT genotype was analysed by real-time polymerase
chain reaction (real-time PCR) assay with allele-specific
TaqMan probes (LightCycler 480 II, Roche).
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Written informed consent was obtained from the rel-
evant guardians of the children and from patients them-
selves, whenever eligible. The study was approved by
the Ethical Committee of the Medical University of
Gdansk, Poland.
Results
Spectrum of NPHS2 mutations in Polish patients
Twenty patients comprising 14 % of the studied cohort fulfilled
the criteria of podocin-associated SRNS. Fifteen were com-
pound heterozygous cases; 11 of these harboured the
c.1032delT mutation and four carried other known mutations.
The remaining five cases showed homozygous mutations
(Table 1).
Ten sequence variants, including three novel ones, were
identified in 34 (24 %) SRNS patients. Variants were located
along the entire coding sequence of the gene. The most
frequent NPHS2 variant was the non-neutral polymorphism
c.686G>A (rs61747728, commonly referred to as p.R229Q),
which was detected in 24 patients (21 %). In 14 of these,
c.686G>A contributed to disease-causing compound hetero-
zygosity, whereas two patients were homozygous and eight
patients were heterozygous for c.686G>Awithout any further
variants in NPHS2. All carriers of the c.1032delT mutation
came from a confined geographical area, the Kashubian re-
gion in North Poland (Fig. 1).
Three novel NPHS2 sequence variants were found. These
included two exonic single nucleotide alterations, c.322A>G
and c.732T>C, present in heterozygous state in individual
patients and an intronic c.872+1G>A substitution present in
homozygous state in a child from a consanguineous marriage.
None of the novel variants is catalogued in the three large
human variation databases: dbSNP, 1000 Genomes andNHLBI
Exome Variant Server. At the protein level, c.322A>G results in
the substitution of a non-conservative residue (p.I108V) by a
similar hydrophobic branched amino acid within the hydropho-
bic intra-membrane domain, while c.732T>C is a silent
(synonymous) mutation. Accordingly, the SIFT and PolyPhen
in silico algorithms advocate for their benign character. None-
theless, the two exonic variants lie near splice-sites at the
exon/intron boundaries and could affect mRNA processing.
Likewise, the third novel variant affects the first nucleotide of
the intron 8 and has been identified by in silico tools as a
mandatory splice-site mutation.
Age of onset and the mutation detection rate
Mutations in the NPHS2 gene were most frequent in patients
diagnosed within the first year of life (26 %, 9/35), and in
patients with congenital nephrotic syndrome in particular
(33 %; 8/24). Toddlers and school children had the lowest
rate of 8 % (7/84). Adolescents diagnosed with the disease
aged over 10 years had an 18 % mutation detection rate
(4/22). All teenagers were compound heterozygous cases for
the c.686G>A polymorphism and an NPHS2 mutation.
Evaluation of the founder effect for NPHS2 mutations
in the Kashubian population
A total of 575 consecutive neonatal dry blood spots represen-
tative for five Kashubian districts of North Poland were evalu-
ated for the p.R229Q polymorphism and the c.1032delT
mutation in NPHS2. The genotype frequencies of the
p.R229Q polymorphismwere consistent with the Hardy–Wein-
berg equilibrium. The p.R229Q minor allele frequency (MAF)
was 6.5% for the entire group (Fig. 1). In the entire cohort, only
one subject from the Koscierzyna district was found to carry a
heterozygous c.1032delT mutation (frequency of the mutated
allele <1/1,000), without any other variants in the NPHS2 gene.
Discussion
Currently, genetic screening in paediatric SRNS is based on
initial testing of the entire coding sequence of NPHS2, with
subsequent extended screening of other genes in line with the
identified phenotype (age at onset, kidney biopsy findings,
presence of extra-renal symptoms) (Santín et al. 2011a).
NPHS2 gene mutations are estimated to account for 10–
30 % of SRNS cases, depending on ethnicity, size of the
analysed group, accuracy of the clinical diagnosis and the
mean age at diagnosis (Santín et al. 2011b). The screening
of the entire coding region of the NPHS2 gene led to a
conclusive diagnosis in 14 % of our unselected consecutive
Polish SRNS cohort, a figure similar to the rates reported for
other European populations (French: Weber et al. 2004;
German: Ruf et al. 2004; Italian: Caridi et al. 2009; Spanish:
Santín et al. 2011b; Hungarian: Kerti et al. 2013). Analysis
of the mutation detection rate with respect to age at onset
revealed the presence of two subgroups with relatively
higher incidence of NPHS2-associated disease: infants and
adolescents. Since mutations in the NPHS2 gene lead to
congenital structural defect of the podocytes, their associa-
tion with the early onset of SRNS is already well acknowl-
edged (Hinkes et al. 2007). Then again, compound
heterozygosity status for p.R229Q has been shown to be
associated with later onset and more latent course of the
disease (Machuca et al. 2009; Lipska et al. 2013). In our
group, all teenagers diagnosed with podocin-associated
SRNS were, indeed, found to be compound heterozygous
for non-neutral p.R229Q, together with an NPHS2mutation.
The criteria for diagnosing podocin-associated SRNS
include a homozygous NPHS2 mutation, compound
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heterozygous NPHS2 mutations or a heterozygous NPHS2
mutation trans-associated with the non-neutral p.R229Q
polymorphism (Machuca et al. 2009). In line with these
guidelines, in the subjects homozygous for the p.R229Q
polymorphism, SRNS was not considered to be caused by
this common podocin variant. Also, a single heterozygous
NPHS2 mutation was not sufficient for diagnosis, as it has
been shown that the presence of a single NPHS2 variant
does not modify the risk of developing the disease (Caridi et
al. 2009).
We noted a geographical cluster of patients carrying the
c.1032delT mutation in North Poland, for the most part in
the Kashubian districts, suggestive of a founder effect
(Fig. 1). Kashubs are an ethnic group of West Slavs who
have populated Northern Poland since the Migration Period
(5th to 7th century A.D.). Despite substantial co-
inhabitation of the region by both Poles and Germans over
the following centuries, this ethnic group has preserved their
cultural identity (Obracht-Prondzynski and Wicherkiewicz
2011). Such a divergence has also been observed on the
genetic level. Confirmation of the genetic distinctiveness of
the Kashubian from other Polish regional populations comes
from studies of serum protein markers and Y-chromosomal
SNPs and short tandem repeats (STRs), which have also
shown hardly detectable German paternal ancestry admix-
ture (Walter et al. 1992; Rębała et al. 2012). Further evi-
dence comes from the recent mutational studies of a few
Mendelian traits, where particular mutations have been al-
most exclusively detected in patients from this region. These
include familiar hypercholesterolaemia (c.662A>G muta-
tion in the LDLR gene; Chmara et al. 2010), familial breast
cancer (c.3700_3704del in the BRCA1 gene; Brozek et al.
2011) and long-chain 3-hydroxyacyl-CoA dehydrogenase
deficiency (c.1528G>A mutation in the HADHA gene;
Piekutowska-Abramczuk et al. 2010). The latter study has
demonstrated a seven times higher incidence rate of this
disorder and proven a founder effect among Kashubian
patients, which led to the introduction of a neonatal screen-
ing programme in the region.
Post-war resettlements resulted in homogenisation of the
contemporary Polish paternal lineages (Rębała et al. 2012). At
present, the population of ca. 550,000 Kashubs is concentrated
in five rural districts of the Pomeranian Region (Fig. 1), ac-
counting for approximately 25 % of its contemporary residents.
All but one of the c.1032delT mutation carriers live in this
region. This mutation has not been catalogued in human vari-
ation databases to date, and the only patient in whom this
mutation was hitherto described lives in Northern Germany
(Hildebrandt, personal communication). However due toWorld
War II-mediated massive human resettlements, one cannot ex-
clude Kashubian origin of this patient.
To test our hypothesis of a Kashubian founder effect, we
performed a population screening study in almost 600 consecu-
tive neonates from North Poland. Only a single subject was
found to be heterozygous for c.1032delT. The frequency of the
non-neutral p.R229Q polymorphism, whichwas trans-associated
with themutation in all the Kashubian SRNS patients, was found
to be two times higher than the average 3.5 % observed in most
European populations (Machuca et al. 2009). The regional par-
ticularities can be readily applied in the diagnostic setting. A cost-
effective approach to genetic testing in patients from the Kashu-
bian regionwould be to pre-screen exons 5 and 8 ofNPHS2 (loci
of p.R229Q and c.1032delT, respectively).
Conversely, NPHS2 mutational analysis in patients living
in other provinces of Poland has to incorporate the entire
coding sequence of the gene. Similarly to studies performed
on other European populations, in the analysed group of
patients, a few rare mutations located in diverse exons have
been diagnosed (Weber et al. 2004; Ruf et al. 2004; Caridi et
al. 2009; Santín et al. 2011b; Kerti et al. 2013). The most
common mutation in Caucasian populations, namely,
p.R138Q, was also the most common in Polish patients (with
Fig. 1 Geographical
distribution of NPHS2 sequence
variants in the Polish
population of steroid-resistant
nephrotic syndrome (SRNS)
patients. Left distribution of the
NPHS2 mutations in Poland.
Right distribution of the NPHS2
mutations in the Kashubian
region of North Poland. Gray
shading districts with the
highest percentage of
Kashubian inhabitants. The
named dots represent major
towns. Minor allele frequency
(MAF) values for the non-
neutral p.R229Q polymorphism
are presented as %
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the exception of Kashubs). This was followed by two muta-
tions typical for Central and Eastern European populations,
namely, c.948delT and p.V290M. These variants have
previously been reported not only in Slavic nations, but
also in German and Hungarian patients (Ruf et al. 2004;
Kerti et al. 2013), echoing the complex history of the
region.
Conclusions
In an unselected national cohort of Polish steroid-resistant
nephrotic syndrome (SRNS) patients, the most commonly
detected mutation was c.1032delT, which was exclusively
detected in patients from Kashubian districts of North Po-
land, suggestive of a founder effect. Most patients carried
compound heterozygous mutations, together with the non-
neutral p.R229Q polymorphism. We recommend first-line
analysis of exons 5 and 8 (the respective loci of p.R229Q
and c.1032delT) in patients from this region.
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